Your Health, We Care
Inhibitors: Avoid concurrent use with P-glycoprotein (P-gp) and strong CYP3A4 inhibitors. Dosage reduction is required when coadministered with P-gp and moderate CYP3A4 inhibitors.
Inducers: Dosage increase is required when coadministered with P-gp and strong CYP3A4 inducers.
Concurrent use may increase the risk of angioedema. Avoid concurrent use.
FDA，2022.02
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
